Prebiotics are food components that are selectively used by gut bacteria, conferring a health benefit, most notably stimulating the growth of bifidobacteria. Accepted prebiotics at present are the fibre types galactooligosaccharides, fructo-oligosaccharides and inulin, some forms of which occur naturally in foods such as pulses, grains, fruit and vegetables. Prebiotics can also be isolated and produced commercially for use as functional ingredients and supplements. The aim of this paper is to provide an overview of the place of prebiotics in a healthy, balanced diet, to explore potential health effects, particularly in relation to gut health, and to consider whether there are implications of consuming a diet low in prebiotics. Dietary fibre is important for health, with high-fibre diets reducing risk of several chronic diseases, via its effects on bowel function, gut microbiota, and cholesterol and glycaemic levels. The prebiotic effects of some fibre types may contribute to these effects. Evidence from supplementation studies carried out in humans suggests that consumption of prebiotics may confer an array of health benefits such as cholesterol lowering, relief of symptoms of gastrointestinal disorders, increased satiety and immunomodulatory effects, though more studies are needed. Findings from observational and intervention studies indicate that exclusion diets, such as low-carbohydrate, gluten-free and the low Fermentable Oligosaccharides, Disaccharides, Monosaccharides and Polyols diet, result in changes to the gut microbiota such as reduced abundance of Bifidobacterium and Lactobacillus species, though whether or not there are any long-term health implications remains unknown. Studies investigating whether prebiotic supplements may be useful in conjunction with such diets (when these are required for medical reasons) to help restore levels of bacteria that are considered to be beneficial, are warranted. Overall, there is a need to promote high-fibre foods across the UK population as intakes currently fall well below recommendations.
Introduction
Increased interest in prebiotics, probiotics and synbiotics (mixtures of pre-and probiotics) has resulted from the explosion of research in recent years into the links between the gut microbiome and gastrointestinal health [e.g. irritable bowel syndrome (IBS) and functional bowel disorders] (Marchesi et al. 2016) . The gut and its microbiota have also been suggested as having a potential role in human metabolism, immunity and even cognitive function. At present, all accepted prebiotics [as per the most recent consensus statement in this area (Gibson et al. 2017) ] are types of dietary fibre (though not all fibre types are prebiotics) and evidence for the health benefits of fibre has strengthened in recent years. The UK Scientific Advisory Committee on Nutrition's (SACN) review of this evidence in 2015 resulted in a change to UK dietary reference values for fibre, increasing from the~24 g/ day [Association of Official Agricultural Chemists (AOAC) fibre] previously recommended for adults to 30 g/day (SACN 2015) . Average intakes in the UK are currently well below this at~19 g/day for adults (Roberts et al. 2018) . New (higher) dietary reference values were also set for children (15 g/day for children aged 2-5 years, 20 g/day for children aged 5-11 years, 25 g/day for children aged 11-16 years and 30 g/day for adolescents aged 16-18 years). These targets are also not being met by the majority of young people (Roberts et al. 2018) . Strong evidence from observational studies suggests significant associations between high-fibre diets and reduced risk of chronic diseases [i.e. cardiovascular disease (CVD), type 2 diabetes and colorectal cancer] (SACN 2015). Randomised controlled trials (RCTs) provide insight into some of the mechanisms behind these links, in that consuming more dietary fibre decreases intestinal transit times, increases faecal bulk and decreases constipation, and particular fibre types have been shown to decrease total cholesterol, low-density lipoprotein (LDL) cholesterol and triacylglycerol concentrations, lower blood pressure, reduce postprandial glycaemia and change faecal bacterial content (EFSA NDA Panel 2011; SACN 2015) . The prebiotic effects of some fibre types may contribute to the health effects of high-fibre diets.
This paper provides an overview of where prebiotics are found in the diet and explores some of their potential health effects, particularly in relation to gut health. It also considers whether there might be any health implications of consuming a diet low in prebiotics.
What are prebiotics?
The concept of prebiotics was introduced in 1995 (Gibson & Roberfroid 1995) , and the most recent definition, based on consensus, is 'a substrate that is selectively utilised by host microorganisms, conferring a health benefit' (Gibson et al. 2017) . In this context, the word 'substrate' implies a substance used for growth through nourishment, with 'selectively utilised' indicating that the effects must extend only to some microbial groups, and not all. Furthermore, to be classed as a prebiotic, a substrate must not confer negative consequences for the host, such as abdominal distension due to excess gas production or the growth of pathogenic microorganisms (Gibson et al. 2017) . Prebiotics can be applied to any tissue with a microbiota (e.g. the skin), though this paper will focus on dietary prebiotics that reach the gut.
The non-digestible carbohydrates known as fructans [including fructo-oligosaccharides (FOS) and inulin] and galactans [including galacto-oligosaccharides (GOS)] are widely accepted as prebiotics (Gibson et al. 2017) , and several 'candidate' prebiotics have been described in the literature. Candidate prebiotics are food components that have demonstrated prebiotic potential in vitro or in animals but for which sufficient data from human studies are lacking (see Table 1 ). All currently accepted prebiotics are carbohydrates, but polyphenols and polyunsaturated fatty acids may fit the criteria in time as evidence gathers (Gibson et al. 2017) .
Currently accepted prebiotics increase bifidobacteria in the human gut (SACN 2015; So et al. 2018) . This is thought to benefit human health through the displacement of pathogens and modulation of the immune system (Wallace et al. 2011) . The structure of fructans and galactans explains their bifidogenic effect (ability to stimulate the growth of bifidobacteria) as these carbohydrates contain linkage bonds that are respectively degraded by the enzymes b-fructosidase (produced by bifidobacteria, lactobacilli and bacteroides) and b-galactosidase (produced by bifidobacteria) (Wilson & Whelan 2017) . Additionally, bifidobacteria preferentially metabolise substrates with chain lengths of the size of oligosaccharides (Gibson et al. 2017) . However, individual variation in responses to prebiotics has been described in relation to bifidogenicity, likely due to the baseline gut microbial composition of the host (Simpson & Campbell 2015) .
international dietary guidelines (Australian Government Department of Health 2015; PHE 2016; The Netherlands Nutrition Centre Foundation 2018; WHO 2018). The prebiotic content of a range of foods, derived from analysis carried out in Australia using consistent methodology, can be seen in Table 2 . Quantities found within individual foods are somewhat lower than doses provided in studies (described in the next section) in which isolated prebiotics are given as a supplement.
Galacto-oligosaccharides normally comprise between two and 10 molecules of galactose and one molecule of glucose. Shorter chain GOS, such as raffinose, stachyose and verbascose, are commonly found in pulses (see Table 2 ) (Brummer et al. 2015) . These types of GOS are referred to as 'a-GOS' as they consist of a-linked galactose, a-linked glucose and a terminal b-linked fructose (Wilson & Whelan 2017) . Due to the presence of three different bonds, a-GOS (found within plant foods) have been found to stimulate the growth of a wider range of gut bacterial species than 'b-GOS', which are derived from the enzymatic glycosylation of lactose, contain terminal b-linked glucose (Goulas et al. 2007) Carlson et al. (2018) . *Described as dietary carbohydrates that show some fermentation selectivity when tested in laboratory systems, but for which evidence from human studies is lacking. List may not be exhaustive; more recently, guar gum, lactulose and resistant maltodextrins have also been suggested as prebiotics (Carlson et al. 2018) . and more selectively stimulate bifidobacteria (Vulevic et al. 2004) . Therefore, b-GOS have predominantly been investigated in human studies rather than plantderived a-GOS (Wilson & Whelan 2017) . Different b-GOS mixtures can be produced synthetically depending on the source of the b-galactosidase enzyme used, and evidence suggests that these have differing bifidogenic effects in the human gut (Depeint et al. 2008) . Isolated GOS can be added to fruit and milk beverages and dairy products (Stephen et al. 2017) . GOS and FOS mixtures are also added to some infant formula and baby foods, due to suggested efficacy in reducing allergy risk (Osborn & Sinn 2013) .
Fructans are composed mainly of chains of fructose units with a terminal glucose molecule, and there are different types including the short-chain FOS, nystose, kestose (comprising fructose and sucrose molecules) and longer chain inulin (Flores-Maltos et al. 2016) . FOS are found in fruit, vegetables and cereal-based foods (see Table 2 ) and can be synthesised from the transfructosylation of sucrose or the enzymatic degradation of inulin (Singh et al. 2016) . Inulin consists of fructose monomers and is present within foods such as chicory, leeks, asparagus, onions, wheat, garlic, oats, soya beans and Jerusalem artichokes (Schaafsma & Slavin 2015) . Inulin purified from chicory root can be used to replace fat and sugar in products, and its use by the food industry may increase in the light of government targets to encourage reformulation of certain food categories (PHE 2018) . At present, inulin is added to some milk powders, 'growing up' milks, bakery products, cereals and cereal bars (Stephen et al. 2017) . Under European Union (EU) novel food regulations, inulin and types of FOS and GOS that have been widely consumed in the EU before 1997 (i.e. have a history of consumption) are considered safe (Gibson et al. 2017 ). However, FOS or GOS preparations produced after 1997 with a different degree of polymerisation or from a different source or production method may be considered a novel food, in which case proof of safety would be required (Kumar et al. 2015) .
Intakes of prebiotics in the UK
Prebiotics are not quantified in standard food composition tables such as the UK's McCance and Widdowson's The Composition of Foods (Finglas et al. 2015) , and data on intakes in populations are scarce. Intake of inulin from natural dietary sources in European countries was reported to be 3-11 g/day in 1995, though this was based on consumption data from 1987 (Van Loo et al. 1995) . Although old data, these figures suggest that intakes are likely to be substantially below doses used in supplement studies (see below). The total fructan content of commercially available breads in the UK has been reported to be 0.86 g/100 g for white sliced bread and 0.88 g/100 g for wholemeal sliced bread (Whelan et al. 2011) , higher than those reported for breads available in Australia (see Table 2 ). Based on data from the National Diet and Nutrition Survey (NDNS) Years 1-4 (collected in 2008-2012) (Bates et al. 2014) , which found adults to be consuming 52 g of white bread and 17 g of wholemeal bread per day on average, it could be estimated that UK adults are consuming 0.6 g of fructans per day from bread alone. A UK study estimated total habitual consumption of 3.6 g/ day of FOS and 2.0 g/day of GOS (Staudacher et al. 2012) , using compositional analysis of starchy foods, fruit, vegetables and pulses carried out in Australia (Muir et al. 2007 (Muir et al. , 2009 Biesiekierski et al. 2011 ). An earlier study by the same group estimated intakes of inulin and oligofructose to be approximately 4.0 and 3.8 g/day, respectively, based on a food frequency questionnaire (FFQ) (Dunn et al. 2011) analysed using compositional data of foods sourced from Europe (Van Loo et al. 1995) . However, it is important to note that these two studies were carried out in individuals with IBS, a group in which dietary intakes may be different from the average population. A casecontrol study, also from the UK, investigating dietary intake in patients with Crohn's disease, reported average total fructan intakes of 3.9 g/day among healthy controls (n = 106) (Anderson et al. 2015) . The main sources of fructans were wheat, onion, banana and garlic. As product reformulation increasingly involves the use of prebiotic ingredients, more recent data on food composition would be useful for assessment of current prebiotic intakes. As research interest in prebiotics grows, analysis of an increasing number of foods is being undertaken, including foods commonly consumed by ethnic minority groups in the UK (Prichard et al. 2016) and foods suitable for vegetarian and vegan diets (Tuck et al. 2018) , using standard methodology which will aid comparisons between foods. Analysis of a wider range of foods will support more complete estimates of UK intakes of prebiotics in future.
Key points
• Food components that are accepted as prebiotics at present are the fibre types fructans (FOS and inulin) and galactans (including GOS).
• Prebiotics can stimulate the growth of bifidobacteria in the gut.
• Fructans are present in some fruit, vegetables and cereal-based foods.
• Galactans include a-GOS (present within plant foods such as pulses) and b-GOS, which can be enzymatically produced from lactose.
• Isolated prebiotics can be used as functional food ingredients to aid product reformulation (e.g. by replacing fat and sugar).
• Recent data on the prebiotic contents of UK foods and current UK intakes are scarce, but average intakes are estimated to be around 4 g of inulin, 4 g of FOS and 2 g of GOS per day.
Isolated prebiotics in the context of fibre definitions
The definition of fibre recommended for use in the UK by SACN is 'all carbohydrates that are neither digested nor absorbed in the small intestine and have a degree of polymerisation of three or more monomeric units, plus lignin', chemically determined using the prevailing AOAC method (SACN 2015) . This is in line with the European Food Safety Authority (EFSA) definition of fibre (EFSA NDA Panel 2010), and the AOAC method 2009.01 is able to determine all the fibre types included in these definitions (i.e. all resistant starches, lignin, inulin, non-digestible oligosaccharides and polydextrose).
Historically, in its Statement on Dietary Fibre published in 2008, SACN stated that for extracted natural carbohydrate components or synthetic carbohydrate products (e.g. prebiotic preparations) to be defined as dietary fibre, beneficial physiological effects, similar to those demonstrated for the naturally integrated dietary fibre component of foods (such as increasing stool bulk, decreasing intestinal transit time and constipation, or the lowering of total cholesterol and LDL-cholesterol concentrations), must be demonstrated by accepted scientific evidence and that evidence limited to effects only on gut fermentation or the nature of the microbiota is not sufficient (SACN 2008) .
On review of the evidence for its 2015 Carbohydrates and Health report, SACN concluded that nondigestible oligosaccharides (which are accepted prebiotics), resistant starch and polydextrose (considered to be candidate prebiotics) increase faecal mass and therefore can be considered as dietary fibre. However, as most of the evidence for the health benefits of fibre comes from studies that considered fibre intake from a wide range of foods (e.g. fruit, vegetables and wholegrains) where it is naturally present as an integrated component, and these foods also contain other components, such as micronutrients and phytochemicals that may also confer a health benefit, SACN recommended that fibre intake should be achieved through a variety of food sources (SACN 2015) .
Health effects of fibre types
As well as demonstrable acute physiological effects of fibre within the gut, there is strong evidence from prospective cohort studies that high-fibre diets are associated with decreased risk of colorectal cancer, type 2 diabetes and CVD (SACN 2015) . The composition of the gut microbiota has also been linked to these conditions (Marchesi et al. 2016) , but the direction of the relationships and the main microorganisms involved are not yet well defined.
RCTs have demonstrated beneficial effects of increasing total dietary fibre intake on intestinal transit times and faecal mass (SACN 2015) . Health effects of specific fibre types are also indicated (e.g. cereal fibre consumption helps to relieve constipation; higher intake of oat bran and isolated b-glucans leads to lower total cholesterol, LDL-cholesterol and triacylglycerol concentrations and lower blood pressure; and non-digestible oligosaccharides, resistant starch, polyols and polydextrose increase faecal mass).
Fibre intakes in the UK are well below recommendations in all age groups (see Table 3 ). These low intakes reflect the many potential barriers to consumption of high-fibre foods, including food preferences, price, convenience and the popularity of exclusion diets that may promote low-fibre intakes (Lockyer et al. 2016) .
Microbial fermentation of fibre
Gut microbes ferment substrates including fibre that escape absorption in the small intestine during digestion, and produce a wide range of metabolites, including short-chain fatty acids (SCFAs) such as acetate, propionate and butyrate. SCFAs shape the gut environment, influence the physiology of the colon, can be used as energy sources by colonic epithelial cells and the intestinal microbiota, and participate in different host signalling mechanisms. In addition, SCFAs stimulate gut hormone release (Kataoka 2016 ) and this mechanism has been suggested to explain why high-fibre foods may be more satiating than low-fibre foods (Chambers et al. 2015) .
As well as the substrates available, the production of SCFAs will partly be determined by the composition of the bacterial species present in the gut (Bik et al. 2017) , and the specific types of SCFAs produced through microbial fermentation may have distinct health effects. Butyrate is the preferred energy source for colonic epithelial cells and is thought to be important for host health including acting as an anti-carcinogen locally (Canani et al. 2011; O'Keefe 2016) . This is one possible explanation for the protective effect of fibre against colorectal cancer, along with decreased transit time and increased faecal bulk, which both decrease contact between harmful compounds in waste and the lining of the gut (WCRF/ AICR 2018). Two types of bacteria that are stimulated by prebiotics, bifidobacteria and lactobacilli, produce mainly lactate and acetate. Thus, the reasons for the enhanced butyrate production reported in prebiotic supplementation studies are unclear. One suggested explanation is that prebiotics also stimulate the growth of butyrate-producing species or other members of the microbiota, which release metabolites that in turn stimulate butyrate production by other microorganisms. This phenomenon could constitute a 'cross-feeding effect' (De Vuyst & Leroy 2011; Cockburn & Koropatkin 2016) .
Diet is a major regulator of the gut microbiota, and certain types of dietary fibre may modify bacterial numbers and metabolism, including SCFA generation. A systematic review and meta-analysis was recently undertaken to assess the effect of dietary fibre interventions (vs. placebo/low-fibre comparators) on gut microbiota composition in healthy adults (So et al. 2018) . The outcomes were between-group differences in the global composition of faecal microbiota (measured by a-diversity) and in species-level abundances at the end of the intervention.
Sixty-four RCTs involving 2099 subjects were included. The fibre interventions most often used were supplements (n = 52 studies) (e.g. FOS, GOS, inulin, xylo-oligosaccharide), compared most frequently with placebo, maltodextrin or sugars. The studies were 14-70 days in duration and fibre doses ranged from 2.1 to 45 g/day. Twelve studies used food-based interventions either with whole diet patterns (high fibre vs. low fibre; wholegrain vs. refined grain) or with a particular food (e.g. rye bread vs. white bread; wholegrain cereal vs. non-wholegrain or wheat bran cereal). The duration of these studies was 14-90 days, with approximate difference in fibre intake of 4-30 g/day.
Overall, the review found that dietary fibre interventions vs. placebo/low-fibre controls increased the abundance of both Bifidobacterium species (standardised mean difference 0.64; 95% CI: 0.42, 0.86; P < 0.00001) and Lactobacillus species (standardised mean difference 0.22; 95% CI: 0.003, 0.41; P = 0.02) particularly in interventions that involved accepted prebiotic fibres, fructans and galacto-oligosaccharides (see Box 1 for more details). Dietary fibre interventions also resulted in higher faecal butyrate concentrations. However, no between-group differences were found for total or other SCFA concentrations (faecal acetate and faecal propionate) or abundances of other pre-specified bacterial groups [Faecalibacterium prausnitzii (13 studies), Roseburia species (4 studies), Eubacterium rectale (2 studies) and Ruminococcus bromii (3 studies)], though the number of studies investigating these bacteria was lower than for Bifidobacterium and Lactobacillus species.
The authors suggest that subgroup analysis showing an effect of dietary fibre supplements on Bifidobacterium species and Lactobacillus species, but no effect with food interventions may be explained by the small sample sizes in the food intervention studies, and because these were largely based on cereal/grains rather than a diverse range of fibre-rich foods.
The primary outcome of the systematic review by So et al. (2018) was between-group differences in a-diversity of the gut microbiota, a measure of both the richness (number of taxonomically distinct organisms present) and the evenness (relative abundances of organisms) of its composition. Cross-sectional studies have identified lower microbial diversity in individuals with conditions such as IBS, Crohn's disease and ulcerative colitis compared to healthy controls (Dicksved et al. 2008; de Vos & de Vos 2012 ; Zhernakova et al. 2016) and, interestingly, microbial diversity has been observed to increase after gastric bypass surgery carried out in obese subjects (Aron-Wisnewsky & Clement 2014). While such evidence suggests that low microbial diversity could be undesirable in relation to health, it is difficult to distinguish whether low diversity occurs as a result of developing a disease or if it was present before onset. Furthermore, it has been argued that gut microbial composition alone is too crude a measure to relate to health and that function is more important (Rowland et al. 2018) .
Based on six RCTs that reported data suitable for inclusion in the meta-analysis (investigating polydextrose, xylo-oligosaccharide, polysaccharopeptide, arabinoxylans and a high-fibre diet), fibre had no effect on a-diversity compared with control (So et al. 2018) . Of a further seven studies reporting a-diversity that were not included in the main meta-analysis, two reported increases in diversity after the consumption of resistant starch type 2 (Alfa et al. 2018) and polydextrose (Costabile et al. 2012) , with the remaining studies finding either no significant difference (for raffinose and resistant starch) (Fernando et al. 2010; Mart ınez et al. 2010) , conflicting results (for arabinoxylans) (Salden et al. 2018) or not reporting group differences (for flaxseed mucilage) (Brahe et al. 2015) . The authors point out that this finding is inconsistent with observational studies that have reported a positive correlation between fibre intake and microbial diversity, when comparing populations from developed and developing countries (De Filippo et al. 2010; Schnorr et al. 2014) and may be explained by differing methodologies used for measuring diversity. So et al. (2018) did not carry out subgroup analysis by fibre type and, at present, there are few studies that have measured the effect of prebiotics on microbial diversity. The net results of selective stimulation of beneficial species, the growth of which produces an unfavourable environment for pathogenic species due to the production of metabolites which reduce intestinal pH, and the stimulation of other species, may vary between individuals due to the baseline composition, prebiotic dose and wider composition of the diet; therefore, affects on diversity may be difficult to predict (Holscher 2017) .
Key points
• Diets higher in fibre are associated with a decreased risk of CVD, type 2 diabetes and colorectal cancer.
• RCTs demonstrate that fibre decreases transit time and increases faecal bulk, reducing constipation. Some fibre types also reduce glycaemic response and cholesterol.
• In the UK, average fibre intakes are below recommendations in all age groups.
• It is recommended that fibre is consumed from a variety of sources.
• In 2015, SACN concluded that isolated non-digestible oligosaccharides (prebiotics), and some 'candidate' prebiotics (resistant starch and polydextrose), increase faecal mass and therefore can be considered as dietary fibre.
Box 1 Effect of fibre intervention on the abundance of (1) Bifidobacterium and (2) Lactobacillus species (So et al. 2018) Bifidobacterium species In a meta-analysis, 51 studies (n = 1629) investigated the effects of fibre interventions on Bifidobacterium species. Dietary fibre led to a significantly higher abundance compared with placebo/low-fibre comparators, with considerable study heterogeneity (I 2 = 85%). There was no difference in effect between doses (from <5 to >10 g/day). In subgroup analysis, intervention fibres classified as either 'accepted' or 'candidate' prebiotics [categorised by the authors as per Roberfroid et al. (2010) , summarised in Table 1 ], as well as interventions delivered as supplements, resulted in significantly higher increases in Bifidobacterium species abundance, whereas 'general' fibre types (including a variety of food interventions and fibre supplements not categorised as accepted or candidate prebiotics such as arabic gum, raffinose and wheat bran extract) did not. However, heterogeneity remained high in all analyses.
Lactobacillus species Data from 24 RCTs (n = 734) showed an overall positive effect of dietary fibre intervention compared with placebo/low-fibre comparators on Lactobacillus species abundance, with subgroup analysis again revealing a significant effect from fibre supplements but not from food interventions. There was no difference in effect between doses (from <5 to >10 g/day). Furthermore, accepted prebiotic fibres significantly increased Lactobacillus species abundance vs. control, but there was no difference for candidate prebiotics or general fibre types vs. control.
• A recent systematic review and meta-analysis of RCTs confirmed that prebiotics stimulate the growth of Bifidobacterium and Lactobacillus species, whereas general fibre types do not.
Potential health effects of prebiotics
Early interest in prebiotics sparked from the discovery that oligosaccharides in breastmilk (human milk oligosaccharides, HMOs) are important for the development of babies' intestinal microbiota (Gibson et al. 2017) . More recently, research has focused on potential effects of prebiotics in adults, including potential amelioration of gut disorders. However, research in this area is still emerging, with fewer published studies compared to probiotics. For example, consumption (n = 159) of 5.5 g/day of a b-GOS mixture for 7 days before travelling (for a minimum of 2 weeks) to a country of medium or high risk for travellers' diarrhoea significantly reduced the incidence, duration and associated abdominal pain of the condition vs. a placebo (Drakoularakou et al. 2010) . In a larger study (n = 334), 2.7 g of b-GOS consumed for 5 days prior to travelling for 7-15 days significantly reduced diarrhoea incidence, though there was no effect on duration or severity (Hasle et al. 2017) . In contrast, another study (n = 244) found that 10 g of FOS consumed daily for 2 weeks before travelling had no significant effect on travellers' diarrhoea (Cummings et al. 2001) . Several studies have found inulin to reduce constipation in both adults and children (Marteau et al. 2011; Collado Yurrita et al. 2014; ClosaMonasterolo et al. 2017) .
Irritable bowel syndrome is a chronic gastrointestinal disorder in which recurrent abdominal pain is associated with defecation or a change in bowel habits. Disordered bowel habits are typically present (i.e. constipation, diarrhoea or a mix of constipation and diarrhoea), as are symptoms of abdominal bloating/distention (Lacy et al. 2016) . The composition of the gut microbiota has been suggested to play a role in IBS, with lower abundance of bifidobacteria and reduced diversity and richness of species often observed in patients, pointing to a potential therapeutic role for prebiotics (Staudacher & Whelan 2016) . Consumption (n = 44) of 3.5 g per day of a b-GOS mixture for 4 weeks significantly improved some IBS symptoms (i.e. flatulence, bloating and subjective global assessment scores of symptom relief) but not abdominal pain vs. placebo, and a 7 g/day dose significantly reduced anxiety and improved self-reported quality of life assessed through a validated IBSspecific questionnaire (Silk et al. 2009 ). Bifidobacteria in the gut increased to similar levels as those seen in healthy subjects after the intervention, with the 7 g dose being more bifidogenic than the 3.5 g dose, but surprisingly the 3.5 g dose appeared to be more clinically effective. Conversely, in a small study (n = 21), 6 g of FOS, consumed daily for 4 weeks, made no improvements to IBS symptoms vs. sucrose (Hunter et al. 1999) . In a later study (n = 96) that used a higher dose of FOS (20 g), no significant differences were found in IBS symptoms after 12 weeks' consumption of FOS vs. a placebo (Olesen & Gudmand-Hoyer 2000) . Similarly, another study (n = 79) that provided 5 g/day of short-chain FOS for 4 weeks found no significant effect on IBS symptoms and quality of life scores vs. placebo (Azpiroz et al. 2017) . In subjects recruited from the general population with a self-reported functional bowel disorder (but no diagnosis of IBS), 2 weeks' consumption of a b-GOS preparation (2.75 g/day) significantly reduced bloating, flatulence, abdominal pain and urgency vs. placebo, but had no effect on the participants' number of bowel movements, consistency of stools, quality of life or mood (Vulevic et al. 2018) . While the studies to date on prebiotics and IBS are limited and findings inconsistent, the two trials described above hint that b-GOS could potentially be beneficial in improving gastrointestinal symptoms in subjects with IBS. No benefit has to date been demonstrated with FOS. This has been suggested to be due to the absence of fructose within b-GOS (Vulevic et al. 2018) [which is present within FOS and inulin; see later section on the low-Fermentable Oligosaccharides, Disaccharides, Monosaccharides and Polyols (FODMAP) diet] and/or the targeted stimulation of bifidobacteria, which do not produce gas (Falony et al. 2009) , though cross-feeding can occur between bifidobacteria and species that do produce gas (De Vuyst & Leroy 2011) . A detailed study carried out in healthy subjects noted that while flatulence does initially increase after supplementation with b-GOS, levels return to baseline within a couple of weeks (Mego et al. 2017) . Gas production correlated with changes in the gut microbiota, which likely resulted in less gas being produced and more being consumed by microbes. More studies are needed to explore whether findings suggestive of a benefit to IBS patients from consumption of b-GOS can be replicated in larger groups, as well as the optimum dose and duration of intake associated with benefit.
There has also been interest in the relationship between the gut microbiome and metabolic health, although understanding of the role of prebiotics in this context is still in its infancy. A series of rodent studies from the Metabolism and Nutrition Research Group at Universit e Catholique de Louvain found that prebiotics changed the rodents' gut microbiota and resulted in reduced weight gain and improved glucose metabolism (Cani et al. 2004 (Cani et al. , 2006 (Cani et al. , 2009b , findings that have been replicated by others (Paul et al. 2016) . FOS intake has been noted in several animal and human studies to affect satiety and food intake and to modulate the production of gut hormones (Cani et al. 2009a; Parnell & Reimer 2009; Verhoef et al. 2011; Hume et al. 2017) . These effects have potential relevance to weight loss and weight maintenance and are thought to be due to increased production of SCFAs in the gut which stimulate cells that produce gut hormones. Increased SCFA production has also been described after consumption of the candidate prebiotic, resistant starch (Lockyer & Nugent 2017) . Interestingly, a prospective cohort study carried out in Spain (n = 8569 university graduates, mean age 37 years, median follow-up 9 years) reported that risk of overweight was 15% and 17% lower for subjects in the highest quartiles of fructan and GOS consumption, respectively (Perez-Cornago et al. 2015) . The main sources of fructans were asparagus, bread, watermelon, biscuits, breakfast cereals and oranges, and the main sources of GOS were bread, breakfast cereals, peas, lettuce, beans and chickpeas. Compared to subjects in the lowest quartile of prebiotic intake (mean total intake 1.1 g/day), subjects in the highest quartile (3.7 g/day) were more likely to be non-smokers, female, older, more physically active and have a higher total fibre intake, lower intake of sugars-sweetened beverages and higher adherence to the Mediterranean diet. However, curiously, subjects in the highest quartile also had a higher total energy intake and higher consumption of fried foods, despite being less likely to be overweight. It is worth noting that dietary assessment was carried out using a validated FFQ at baseline and 10 years later, but only 26.9% of subjects completed the FFQ at both time points.
In its 2015 Carbohydrates and Health report, SACN considered studies investigating the link between nondigestible oligosaccharides and inulin and a range of health outcomes relating to metabolic health (see Table 4 ). RCTs in which diets were supplemented with non-digestible oligosaccharides demonstrated a beneficial effect on fasting blood lipid concentrations, but no effect on fasting glucose and insulin concentrations or energy intake. Furthermore, non-digestible oligosaccharides were found to result in an increase in faecal mass and affect faecal bacterial content (including increasing bifidobacteria), but not faecal SCFA levels (data on the latter two effects could not be FOS, fructo-oligosaccharides; RCTs, randomised controlled trials; LDL-C, low-density lipoprotein cholesterol; TC, total cholesterol; HDL-C, high-density lipoprotein cholesterol; TAG, triglycerides; GOS, galacto-oligosaccharides. P values highlighted in bold indicate effects that were found to be statistically significant.
pooled and so effect sizes are not reported in Table 4 ). Non-digestible oligosaccharides or inulin supplementation were found to increase fractional absorption of calcium in children, but not in adults, though whether this effect is of biological relevance and benefit is currently unclear. SACN commented that the supplement doses used in the studies considered were above levels currently consumed in typical diets in the UK. Direct interaction between prebiotics and the immune system has been suggested (Vos et al. 2007 ). Animal and in vitro studies have indicated that prebiotics can not only stimulate the growth of bifidobacteria but also provide protection against infection by opportunistic pathogens, such as Escherichia coli and Salmonella enterica, by preventing their adhesion to the gut mucosa and invasion into tissues (Tzortzis et al. 2005; Apanavicius et al. 2007; Searle et al. 2009; Gouveia et al. 2013) . Inulin-type fructans have been noted to impact upon gut immune markers (Vogt et al. 2015) , although the evidence in humans is very limited, and there is some evidence that consumption of prebiotics may prevent acute infections in young children (Lohner et al. 2014; Luoto et al. 2014) .
European Union health claims
Although several health claim dossiers for prebiotics, relating to GOS, FOS, inulin and other food components described as having prebiotic activity, have been submitted, to date these have been given a negative Opinion by EFSA resulting in them being unsuccessful (European Commission 2016). The reasons provided for this outcome included that some of the proposed health effects, such as 'increasing numbers of gastrointestinal microorganisms', are not deemed to be beneficial physiological effects as defined and required by the Nutrition and Health Claims Regulation [Regulation (EC) (EFSA NDA Panel 2016); the claimed effect was vague and had not been sufficiently defined to enable assessment (e.g. 'digestive health benefits') (EFSA NDA Panel 2011); and that the food or ingredient had not been sufficiently characterised for a scientific assessment of the claimed effect to be completed (EFSA NDA Panel 2009).
According to EFSA, 'decreasing potentially pathogenic gastrointestinal microorganisms' might be a beneficial physiological effect and this has been the subject of several dossiers but in all cases, these claims were unsuccessful as the claimed effect was not substantiated based on the scientific evidence submitted (European Commission 2016). A proprietary health claim [one that can only be used by the applicant, due to the claim being based on pertinent proprietary (confidential and unpublished) scientific evidence belonging to the applicant] has been accepted for use within the EU relating to native inulin from chicory contributing to normal bowel function by increasing stool frequency (EFSA NDA Panel 2015). The claim can be used only for food which provides at least a daily intake of 12 g of native chicory inulin.
Are diets low in prebiotics detrimental to gut health?
It is widely accepted that diets low in fibre can have adverse effects on gut health. This is because fibre is a key nutrient for a healthy microbiome, acting as a substrate for fermentation by gut bacteria that produce thousands of enzymes for this purpose (El Kaoutari et al. 2013) . If fibre is unavailable, dietary fatty acids and amino acids that reach the large intestine, or indeed endogenous components such as proteins or the mucus layer present within the gut (which has a high polysaccharide content), are fermented for energy by gut microbes instead (Brownlee et al. 2003; Hedemann et al. 2009; Earle et al. 2015; Desai et al. 2016; Koh et al. 2016) . Such a scenario may not be favourable to human health as SCFA production is likely to be affected (den Besten et al. 2013 ) and the degradation of mucus (as illustrated in a gnotobiotic mouse model) may lead to increased gut barrier permeability with the potential of increased pathogen infection (Desai et al. 2016) . Research has now begun to investigate the effects of popular diets that may potentially reduce fibre intake by avoidance of fibre-rich foods such as wholegrains (e.g. low-carbohydrate and gluten-free diets).
Low-carbohydrate diets and gut microbiome
Low-carbohydrate, high-protein/high-fat diets have gained popularity in recent years as a weight loss strategy, with purchases of traditional staple starchy foods, such as bread and potatoes, declining steadily over recent decades in the UK (Defra 2018) . Surveys carried out in the UK on behalf of the Food Standards Agency suggest that consumers have a poor perception of starchy foods, describing them as 'fattening', 'stodgy', 'heavy', 'bloating', with many trying to 'cut down' on these foods in order to lose weight (Ipsos Mori 2012; FSA 2014) . Categorisation of all types of carbohydrates (sugars, refined grains and wholegrains) as one group may have resulted in all types being perceived to have a negative impact upon health. Lowcarbohydrate intakes are not typical of healthy dietary patterns, such as Mediterranean and plant-based diets, which include wholegrains as a key component and are therefore rich in fibre.
Low-fibre diets have been associated with different gut microbial compositions compared to higher fibre diets. For example, a small observational study which compared children aged 2-6 years from Burkina Faso (a rural African population) and Florence, Italy (an urban European population) reported that the African children, who had a higher fibre intake (of~10-14 g/day, vs.~6-8 g in European children), had increased richness and biodiversity in their faecal microbiota vs. European children and specifically possessed Prevotella, Xylanibacter and Treponema species that metabolise fibre, generating SCFAs (total faecal SCFAs were higher in the African children) (De Filippo et al. 2010) . Larger, similar studies have also noted differing predominant microbiota when comparing individuals from the US, consuming a more 'Western' style diet, with those in less developed countries, consuming a more agrarian (cerealbased) diet (Yatsunenko et al. 2012; Lin et al. 2013) , and when comparing long-term higher vs. lower fibre consumers (Wu et al. 2011) , although other genetic and environmental factors are likely to also contribute to these differences. Interestingly, a recent study has shown that migration to the US from Thailand is associated with a loss of bacterial enzymes linked to fibre degradation and a loss of gut microbial diversity (Vangay et al. 2018) . Higher production of SCFAs has also been demonstrated with higher fibre intakes, for example in a study comparing African Americans to native Africans (who have typically higher fibre diets) (Ou et al. 2013) .
A randomised crossover study of 19 obese subjects reported significant decreases in butyrate-producing Roseburia species and Eubacterium rectale, bifidobacteria and faecal butyrate after the consumption of a high-protein, low-carbohydrate diet for 4 weeks when compared to a high-protein, medium-carbohydrate diet (see Table 5 ) (Duncan et al. 2007) . In a similar crossover study, 17 obese men were prescribed a high-protein, moderate-carbohydrate diet and a highprotein, low-carbohydrate diet, both consumed for 4 weeks after an initial weight maintenance diet which was consumed for 7 days (see Table 5 ) (Russell et al. 2011) . Faecal concentrations of total SCFAs, acetate and butyrate were significantly lower after the low-carbohydrate diet vs. the moderatecarbohydrate diet. Abundance of the butyrate-producing bacteria Roseburia/Eubacterium rectale was significantly lower after the low-carbohydrate diet compared to the high-carbohydrate diet, but the abundance of Faecalibacterium prausnitzii, which also produce butyrate, was maintained. Faecal concentrations of phenolic compounds and their metabolites were lower after the low-carbohydrate diet, and the authors reported higher concentrations of carcinogenic N-nitroso compounds vs. the weight maintenance diet. In a larger study, 91 obese subjects consumed isocaloric low-carbohydrate or high-carbohydrate diets for 8 weeks (Brinkworth et al. 2009 ). Faecal bifidobacteria, total SCFAs and butyrate were significantly lower in the low-carbohydrate group vs. the high-carbohydrate group (see Table 5 ). In a small study (n = 9 individuals completed both arms) investigating isocaloric diets that exclusively consisted of animal foods (meat, cheese, eggs, cream; low-carbohydrate, devoid of fibre) or plant foods (grains, fruit, vegetables and pulses; high-carbohydrate, high-fibre), faecal concentrations of SCFAs derived from carbohydrate fermentation were significantly higher after the plant-based diet and concentrations of SCFAs derived from amino acid fermentation were significantly higher after 5 days' consumption of the animal foods diet, vs. the other treatment (see Table 5 ) (David et al. 2014) . Higher concentrations of SCFAs derived from carbohydrate fermentation correlated with the abundance of saccharolytic (carbohydratemetabolising) microbes and higher concentrations of SCFAs derived from amino acid fermentation correlated with the abundance of putrefactive microbes. Overall, the animal-based diet had a greater impact on gut microbial composition than the plant-based diet.
Evidence suggests that dietary macronutrient composition has an important influence on gut microbial composition with low-carbohydrate, lower fibre diets resulting in potentially unfavourable changes, but longer term studies are needed to ascertain if this is associated with any health consequences. As well as fibre, carbohydrate-containing foods also provide other nutrients such as vitamins, minerals and plant bioactives (e.g. polyphenols), some of which can nourish gut microbes (Conlon & Bird 2014) and may confer other health benefits (Williamson 2017) . Interestingly, emerging research suggests that dietary fibre may enhance the bioavailability of polyphenols in the gastrointestinal tract, both directly through mechanisms that occur as a result of co-ingestion and also indirectly by stimulating the growth of bacterial species that catabolise phenolic compounds (Edwards et al. 2017) . It is also possible that dietary prebiotic content has an impact on the changes in gut microbial composition and SCFA production that have been noted in the above studies, but this has not yet been assessed.
Gluten-free diets and gut microbiome
Another dietary trend that may affect fibre and prebiotic intake is gluten-free diets. Gluten-free was the primary 'free-from' claim being made on products in the UK in 2016 (Mintel 2017) , despite the prevalence of coeliac disease estimated as being only 1% of the UK population (Coeliac UK 2018) . There is a common misperception that a gluten-free diet is generally more healthy than one that contains gluten (Kim et al. 2016) , but studies suggest that glutenfree diets are lower in fibre and some micronutrients and higher in sugar (Vici et al. 2016; Staudacher et al. 2018) . A small study carried out in 10 healthy subjects aged 23-40 years (with no history of digestive pathology) reported significant decreases in Bifidobacterium and Lactobacillus species and significant increases in some opportunistic pathogens such as Escherichia coli in subjects following a gluten-free diet for 1 month (De Palma et al. 2009 ). 'Simple carbohydrate' intakes were noted as being similar before and during the gluten-free diet (74.3 g vs. 72.0 g) but intake of polysaccharides (characterised in this study as 'complex carbohydrates' but not fibre specifically) was significantly lower on the gluten-free diet (116.6 g vs. 63.0 g). The authors speculated that the prebiotic effect of some polysaccharides could be the reason for the changes in microbial composition.
The low FODMAP diet and gut microbiome
The low FODMAP diet is recommended by the National Institute for Health and Care Excellence (NICE) for the management of IBS, if diet continues to be considered a major factor in a person's symptoms and they are following general lifestyle/dietary advice (and provided that advice is given only by a dietitian) (McKenzie et al. 2016; NICE 2017) . Evidence indicates that FODMAPs [short-chain carbohydrates such as fructose, lactose, polyols such as sorbitol and mannitol, and fructans and galactans (prebiotics)] cause symptoms such as bloating, pain and disturbed bowel habits in some individuals due to their fermentation in the large intestine, which produces gas and draws fluid into the intestine (Murray et al. 2014 ). Complete restriction of major sources of FODMAPs in the diet, such as milk, wheat, pulses, honey, some fruit and some sugar alcohols (such as xylitol, found in sugar-free gum), for a recommended 4 weeks is followed by a period of careful FODMAP reintroduction using staged, dosed, FODMAP challenges to find out how the diet can be tailored to the individual moving forward ( Whelan et al. 2018) . Due to the suggestion of potentially unfavourable effects on dietary intake, such as reduced fibre and calcium and changes to the gut microbiota, a low FODMAP diet is not advised for healthy individuals or anyone not under the direction of a dietitian (Gibson & Shepherd 2010) . Short-term studies (3-4 weeks) have indicated that consumption of a low FODMAP diet results in changes to gut microbial composition when compared to a habitual diet (Halmos et al. 2015) including reducing the abundance of bifidobacteria (Staudacher et al. 2012) , an effect that may not be surprising considering that some FODMAPs are prebiotics (fructans, GOS). While effects of the regime on dietary intake, symptoms, acceptability and food-related quality of life have been assessed among patients with IBS after 6-18 months (n = 103) (O'Keeffe et al. 2018), whether there are any long-term effects on the gut microbiota is not known. Interestingly, a recent parallel study (n = 40) comparing the consumption of a prebiotic (b-GOS) supplement alongside a Mediterranean-style diet, with a placebo supplement (xylose) alongside a low FODMAP diet, for 4 weeks in subjects with functional gastrointestinal disorders involving flatulence, reported a significant increase in the abundance of bifidobacteria in the prebiotic group and a significant decrease in the low FODMAP group (Huaman et al. 2018 ). There was a significant reduction in symptoms (pain, distension, bloating) from baseline in both groups, as well as flatulence and borborygmi (gurgling noises) in the low FODMAP group (but not the prebiotic group), but there were no significant differences between the two groups, suggesting that the diets were equally effective, although symptom relief tended to persist for 2 weeks after discontinuation of prebiotic supplementation, but returned immediately after discontinuation of the low FODMAP diet (these differences were not significant). Due to the study design, it is difficult to tease apart the effects of the prebiotic and the Mediterranean diet on symptoms. Indeed, co-administration of a multi-strain probiotic alongside a low FODMAP diet was recently reported to prevent a reduction in bifidobacteria species seen in those taking a placebo (n = 104 IBS patients) (Staudacher et al. 2017) . Further studies investigating whether prebiotic supplement use has benefits for those following a low FODMAP diet are warranted (Staudacher & Whelan 2016) . Full results are awaited from recently completed work in this area (Wilson et al. , 2018 ).
Key points
• There is some evidence that b-GOS may be beneficial in preventing traveller's diarrhoea and in ameliorating IBS symptoms.
• There is some evidence that inulin can relieve constipation.
• There is some evidence that fructans can improve blood lipid profiles.
• A health claim has been accepted for use within the EU relating to native inulin from chicory contributing to normal bowel function by increasing stool frequency. Other EU health claim applications for prebiotics have been unsuccessful.
• Studies have demonstrated that restriction diets associated with low-fibre intake (e.g. low-carbohydrate; gluten-free; low FODMAP diet) can lead to changes in gut microbiota, such as reduced abundance of Bifidobacterium and Lactobacillus species.
• Prebiotic supplements used alongside restriction diets required for medical purposes may prevent such changes, but further investigation is warranted.
Conclusion
Prebiotics, by definition, selectively increase types of bacteria in the gut which are thought to be beneficial to health. Thus, prebiotics differ from most dietary fibres, such as pectins, cellulose and xylans, which encourage growth of a wide variety of gut microorganisms, though there are individual variations in host response. All accepted prebiotics at present are fibre types that are either naturally present in, or produced from, a variety of foods that are encouraged as an important part of a healthy, balanced diet (i.e. fruit, vegetables, pulses, wholegrains).
Among the first prebiotic substances recognised for their ability to influence gastrointestinal health were the oligosaccharides present in human milk. Evidence from human studies providing single prebiotic preparations in supplement form suggests a range of potential benefits on a number of health outcomes (e.g. metabolic health, symptoms of gastrointestinal disorders, satiety, immunomodulatory effects) though more studies are needed in this area, particularly to ascertain the amounts that would need to be consumed, duration of intake required before seeing an effect and how long the effects would last. Less is known about the health effects of intrinsic prebiotics in foods vs. those isolated in supplements. This is difficult to study as the mix of fibre types and other food components (e.g. polyphenols, micronutrients) present in foods makes separating out the specific effects of prebiotics alone complex. The body of evidence for the positive health effects of dietary fibre has grown over recent years, leading to higher UK dietary reference values being set in 2015 (SACN 2015) . However, average daily intakes are well below recommendations in all age groups (Roberts et al. 2018) . Changes in the composition of the gut microbiota have been noted amongst followers of exclusion diets that tend to be low in fibre and/or prebiotics specifically, including low-carbohydrate diets. However, whether this translates into any health effects in the long-term remains unknown.
Information on the quantities and mix of prebiotics habitually being consumed in the UK is lacking and intakes may change in the next few years due to advances in use of prebiotics as a novel food ingredient (SACN 2015) . Although data have begun to be compiled for specific food types, data on the prebiotic composition of a broader range of foods would be useful, for example to enable comparisons of intakes in specific population subgroups or in response to different dietary patterns (e.g. vegetarian diets). It is recommended that a total dietary fibre intake of 30 g/day (for UK adults) is achieved by consuming a variety of fibre-containing foods. Although supplements should not be used in place of a healthy, balanced diet, prebiotic supplements might represent a targeted approach for negating possible negative effects on the gut microbiota of exclusion diets required for medical reasons (such as the low FODMAP diet for IBS and a glutenfree diet for coeliac disease). As research to date has been limited, this certainly warrants further investigation.
